CE vs CUE · rev $10.28B vs rev $9.3M
Celanese Corporation (CE) versus Cue Biopharma (CUE) — a side-by-side from cached financials, not a winner call.
Celanese Corporation (CE) is a chemicals company listed on US.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
CE currently screens at market cap $5.92B. CUE currently screens at market cap $59.5M.
Not investment advice. Open the CE and CUE stock pages for the full models.
Not investment advice.